MiMedx Group (NASDAQ:MDXG - Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect MiMedx Group to post earnings of $0.05 per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.08. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. The business had revenue of $87.21 million for the quarter, compared to analysts' expectations of $88.44 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
MiMedx Group Stock Down 1.7 %
MDXG traded down $0.10 on Wednesday, hitting $5.62. 423,900 shares of the company were exchanged, compared to its average volume of 711,148. MiMedx Group has a twelve month low of $5.47 and a twelve month high of $9.27. The company has a market cap of $829.53 million, a price-to-earnings ratio of 12.82 and a beta of 1.97. The company has a current ratio of 3.85, a quick ratio of 3.22 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average price of $6.13 and a two-hundred day moving average price of $6.70.
Analyst Ratings Changes
A number of equities analysts recently commented on the stock. StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, October 15th. Craig Hallum cut their price objective on shares of MiMedx Group from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, August 1st. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $11.00 target price on shares of MiMedx Group in a report on Thursday, August 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $12.00.
Get Our Latest Stock Report on MiMedx Group
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Recommended Stories
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
